NO961888L - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser - Google Patents

Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser

Info

Publication number
NO961888L
NO961888L NO961888A NO961888A NO961888L NO 961888 L NO961888 L NO 961888L NO 961888 A NO961888 A NO 961888A NO 961888 A NO961888 A NO 961888A NO 961888 L NO961888 L NO 961888L
Authority
NO
Norway
Prior art keywords
alkyl
aryl
amino
alkenyl
inhibitors
Prior art date
Application number
NO961888A
Other languages
English (en)
Other versions
NO961888D0 (no
Inventor
John Montana
Jonathon Dickens
David Alan Owen
Andrew Douglas Baxter
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of NO961888L publication Critical patent/NO961888L/no
Publication of NO961888D0 publication Critical patent/NO961888D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelse med formel (l), hvori R1 er Cj^alkyl, C,_ 6alkenyl, aryl, (C^alkyl) aryl eller C^alkyl-AR9 hvor A er O, NR9 eller S(O)m, hvor m = 0-2, og hver R9 er H, C1_4alkyl, aryl eller (C1_4alkyl) -aryl; R2 er H eller Cx_6alkyl; enten er R4 H eller C^.galkyl eventuelt substituert med amino(NH2), aryl- amino, beskyttet amino, aryl, di(C1_6alkyl) amino, 6alkyl)amino, C02H, beskyttet karboksyl, karbamoyl, 6alkyl)karbamoyl eller di (C^.galkyl) -karbamoyl, og R5 er H eller C^alkyl, eller NR4R5 er pyrrolidono, piperidino eller morfolino; R6 er eventuelt substituert C3_6cykloalkyl, C3_6- cykloalkenyl, C1_6alkyl, benzyl, (C1_6alkoksy) benzyl, benzyl- oksybenzyl eller 3-indolylmetyl; Alk er C^.galkyl eller C2_ 5alkenyl, og n = O eller 1; R7 er H eller R10CO hvor R10 er C±_ 4alkyl, (C1_4alkyl)-aryl, C3_6cykloalkyl, (C3_6cykloalkyl) - C1_4alkyl, C2_6alkenyl eller (C2_6alkenyl)aryl; og R8 er H, C^ 4alkyl, (C1_4alkyl)aryl eller aryl; eller et salt, solvat eller hydrat derav. Slike forbindelser kan anvendes for å behandle tilstander i forbindelse med metalloproteinase, TNF og/eller annen aktivitet.
NO961888A 1993-11-10 1996-05-09 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser NO961888D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (2)

Publication Number Publication Date
NO961888L true NO961888L (no) 1996-05-09
NO961888D0 NO961888D0 (no) 1996-05-09

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961888A NO961888D0 (no) 1993-11-10 1996-05-09 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser

Country Status (21)

Country Link
US (1) US5853623A (no)
EP (1) EP0728144B1 (no)
JP (1) JPH09505041A (no)
KR (1) KR960705843A (no)
CN (1) CN1134705A (no)
AT (1) ATE188969T1 (no)
AU (1) AU679286B2 (no)
BR (1) BR9408025A (no)
CA (1) CA2173470A1 (no)
CZ (1) CZ287780B6 (no)
DE (1) DE69422726T2 (no)
DK (1) DK0728144T3 (no)
ES (1) ES2143611T3 (no)
FI (1) FI961976A7 (no)
GB (1) GB9323165D0 (no)
GR (1) GR3033103T3 (no)
HU (1) HU217344B1 (no)
NO (1) NO961888D0 (no)
PL (1) PL180403B1 (no)
PT (1) PT728144E (no)
WO (1) WO1995013289A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI960803L (fi) * 1993-08-23 1996-04-22 Immunex Corp TNF-alfa-sekreetion inhibiittoreita
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
ES2133807T3 (es) * 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
WO1996035714A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
CA2217859A1 (en) * 1995-05-10 1996-11-14 David Alan Owen Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
BR9610922A (pt) * 1995-10-05 1999-12-21 Darwin Discovery Ltd Peptìdios rio-substituìdos como inibidores para metalo-proteinases e liberação de tnf
AU7139996A (en) * 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
CA2229438C (en) * 1995-11-22 2006-01-17 Chiroscience Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
EP0950656B1 (en) 1996-01-23 2007-04-11 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
PT891187E (pt) * 1996-04-04 2002-06-28 Hoffmann La Roche Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
CA2260859A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
CA2280134A1 (en) * 1997-03-03 1998-09-11 David Alan Owen Selective mmp inhibitors having reduced side-effects
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998038859A1 (en) 1997-03-04 1998-09-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2001523662A (ja) 1997-11-14 2001-11-27 ジー・ディー・サール・アンド・カンパニー 芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000040552A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. Amidomalonamides and their use as inhibitors of matrix metalloproteinase
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AP2001002240A0 (en) 1999-02-08 2001-09-30 Searle & Co Sufamato hydroxamic acid metalloprotease inhibitor.
CA2374555A1 (en) * 1999-06-15 2000-12-21 Merck & Co., Inc. Thiol derivative, metallo-beta-lactamase inhibitors
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
CZ20023179A3 (cs) * 2000-03-21 2003-02-12 The Procter And Gamble Company Metalloproteázové inhibitory zahrnující vedlejší karbocyklický řetězec
CA2401728A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
RU2245876C2 (ru) 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
HRP20030901A2 (en) 2001-05-11 2005-10-31 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
EP2416799B1 (en) 2009-04-10 2017-11-01 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599736B2 (en) * 1986-12-24 1990-07-26 Beecham Group Plc Thiol-carboxylic acid derivatives
EP0358660B1 (en) * 1987-03-17 1994-05-25 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
GB9323165D0 (en) 1994-01-05
WO1995013289A1 (en) 1995-05-18
PT728144E (pt) 2000-07-31
FI961976A0 (fi) 1996-05-09
FI961976A7 (fi) 1996-05-09
CZ134996A3 (en) 1996-10-16
HK1015139A1 (en) 1999-10-08
NO961888D0 (no) 1996-05-09
ES2143611T3 (es) 2000-05-16
US5853623A (en) 1998-12-29
DE69422726T2 (de) 2000-06-08
AU8113394A (en) 1995-05-29
CZ287780B6 (en) 2001-02-14
PL180403B1 (pl) 2001-01-31
HU9601244D0 (en) 1996-07-29
DE69422726D1 (de) 2000-02-24
BR9408025A (pt) 1996-12-17
JPH09505041A (ja) 1997-05-20
GR3033103T3 (en) 2000-08-31
AU679286B2 (en) 1997-06-26
EP0728144B1 (en) 2000-01-19
DK0728144T3 (da) 2000-07-03
ATE188969T1 (de) 2000-02-15
PL314300A1 (en) 1996-09-02
CA2173470A1 (en) 1995-05-18
EP0728144A1 (en) 1996-08-28
HU217344B1 (hu) 2002-02-28
HUT73799A (en) 1996-09-30
KR960705843A (ko) 1996-11-08
CN1134705A (zh) 1996-10-30

Similar Documents

Publication Publication Date Title
NO301880B1 (no) Substituerte heterocykliske karboksylsyreamider og deres anvendelse for fremstilling av legemidler
ZA918893B (en) Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives,process for their production and pharmaceutical agents containing these derivatives
MY108885A (en) Heterocyclic-cyclic amine derivatives.
FI961976A7 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DE60112055D1 (de) Inhibitoren von gamma-secretase
NO962540L (no) Rapamycinderivater for anvendelse som immunsuppresjonsmidler
DE69315079D1 (de) Beta-aminoalkyl und beta-n-peptidylaminoalkylborsäure
ATE150308T1 (de) Hemmung von thrombin
ES2151156T3 (es) Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados.
AU6049696A (en) Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
ATE242206T1 (de) Substituierte derivate von benzosulphonamiden als hemmer des enzym cyclooxygenase ii
GB9300194D0 (en) Piperazine derivatives
NO944918L (no) Hemming av seborre og akne
NO982290L (no) Merkaptoalkylpeptidyl-forbindelser som har en imidazolsubstituent og deres anvendelse som inhibitorer av matriks-metalloproteinaser (MMP) og/eller tumor nekrosefaktor (TNF)
DE69412049D1 (de) Hemmung von dysfunctionalen Uterusblutungen
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
NO943873L (no) Hemming av bruskdegradering
AU2223595A (en) Aziridine derivatives, their production and use
AU9066498A (en) Substituted 6-alkylphenanthridines
ATE203406T1 (de) Hemmung von hirsutismus und alopecia bei frauen
NO984921L (no) Tienopyridinderivater og deres anvendelser
ES2012958A6 (es) Procedimiento para preparar derivados de cisteina.
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
TW353662B (en) Cephalosporin salts and process for the preparation thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application